The present study illustrates its efficiency in a murine model of MS and it will be interesting to study the effect of MALT1 targeting in other inflammatory diseases such as rheumatoid arthritis, psoriasis and inflammatory bowel disease that involve increased T cell receptor signaling. This evidence concerns the gene MALT1 and myeloid sarcoma.